Liquid Biopsies
​
​
Liquid Biopsy in Progressing Prostate Cancer Patients Starting Docetaxel with or Without Enzalutamide: A Biomarker Study of the PRESIDE Phase 3b Trial
Ruiz-Vico M, et al. Eur Urol Oncol. 2024
https://www.sciencedirect.com/science/article/pii/S2588931124001883
Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges (Review)
Trujillo B, et al. Br J Cancer. 2022
https://www.nature.com/articles/s41416-022-01881-9
Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay
Orlando F, et al. NAR Cancer. 2022
https://academic.oup.com/narcancer/article/4/2/zcac016/6594019?login=true
Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study
Conteduca V, et al. Eur J Cancer. 2021
https://www.sciencedirect.com/science/article/pii/S0959804921002719?via%3Dihub
Circulating Androgen Receptor for Prognosis and Treatment Selection in Prostate Cancer
Conteduca V, et al. Eur Urol Oncol. 2021
https://www.sciencedirect.com/science/article/pii/S2588931120302170?via%3Dihub
Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial
Jayaram A, et al. Ann Oncol. 2021
https://www.annalsofoncology.org/article/S0923-7534(21)01074-7/fulltext
Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer.
Conteduca V, et al. Br J Cancer. 2020
https://www.nature.com/articles/s41416-020-0969-5
Genome-wide plasma DNA methylation features of metastatic prostate cancer
Wu A, et al. The Journal of Clinical Investigation. 2020
https://www.jci.org/articles/view/130887
​
Multimodal Approach to Outcome Prediction in Metastatic Castration-Resistant Prostate Cancer by Integrating Functional Imaging and Plasma DNA Analysis
Conteduca V, et al. JCO Precision Oncology. 2019
https://ascopubs.org/doi/10.1200/PO.18.00302
​
Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis
Jayaram A, et al. JCO Precision Oncology. 2019
https://ascopubs.org/doi/full/10.1200/PO.19.00123
​
Plasma DNA Analysis in Prostate Cancer: Opportunities for Improving Clinical Management (Review)
Wu A, Attard G. Clin Chem. 2019.
https://academic.oup.com/clinchem/article/65/1/100/5607912
​
Plasma DNA and Metastatic Castration-Resistant Prostate Cancer: The Odyssey to a Clinical Biomarker Test (Review)
Jayaram A, Wetterskog D, Attard G, Cancer Discov. 2018.
http://cancerdiscovery.aacrjournals.org/content/8/4/392.long
​
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
Conteduca V, et al. European Urology. 2018
https://www.europeanurology.com/article/S0302-2838(18)30739-5/fulltext
​
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
Conteduca V, et al. Ann Oncol. 2017
https://academic.oup.com/annonc/article/28/7/1508/3792654
​
Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer
McDaniel AS, et al. BJU Int. 2017
https://onlinelibrary.wiley.com/doi/abs/10.1111/bju.13631
​
Plasma AR and abiraterone-resistant prostate cancer
Romanel A, et al. Sci Transl Med. 2015
http://stm.sciencemag.org/content/7/312/312re10.full
​
Androgen receptor expression in circulating tumour cells from castration resistant prostate cancer patients treated with novel endocrine agents
Crespo M, et al. Br J Cancer. 2015
https://www.nature.com/articles/bjc201563
​
Tumor clone dynamics in lethal prostate cancer
Carreira S, et al. Sci Transl Med. 2014
http://stm.sciencemag.org/content/6/254/254ra125.full
​
​
​